Sun Pharma Advanced Research Company Announces Quarterly Results and Promoter Reclassification Approval
Sun Pharma Advanced Research Company Ltd released its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following the outcome of a Board meeting held on August 10, 2026. The company's Board approved the financial outcomes and sanctioned requests received for reclassifying certain promoter group individuals from the 'Promoter Group' category to the 'Public' category, subject to necessary approvals.Quarterly Standalone Financial Results (Q ended June 30, 2026)
The company reported key performance indicators across its standalone operations for the quarter ended June 30, 2026. The unaudited results are presented below, with figures in Lakhs:| Particulars | Q ended 30.06.2026 (Unaudited) | Q ended 31.03.2026 (Audited) | Q ended 30.06.2025 (Unaudited) | Year ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from contracts with customers | 3,992 | 1,320 | 964 | 3,915 |
| Other operating revenue | - | 1,84,002 | - | 1,84,002 |
| Total revenue from operations | 3,992 | 1,85,322 | 964 | 1,87,917 |
| Other income | 2,366 | 180 | 902 | 1,083 |
| Total income | 6,358 | 1,85,502 | 1,866 | 1,89,000 |
| Cost of materials consumed | 766 | 516 | 513 | 2,360 |
| Employee benefits expense | 2,416 | 2,108 | 2,768 | 10,185 |
| Clinical trial expenses / products development expense | 1,326 | 284 | 554 | 2,266 |
| Professional charges | 2,124 | 3,480 | 1,436 | 8,753 |
| Finance costs | 813 | 1,164 | 618 | 3,412 |
| Depreciation and amortisation expense | 220 | 240 | 254 | 1,007 |
| Other expenses | 791 | 1,640 | 926 | 4,568 |
| Total expenses | 8,456 | 9,432 | 7,069 | 32,551 |
| Profit / (loss) before exceptional item and tax | (2,098) | 1,76,070 | (5,203) | 1,56,449 |
| Exceptional item | - | - | - | 1,236 |
| Profit / (loss) before tax | (2,098) | 1,76,070 | (5,203) | 1,55,213 |
| Tax expense | - | - | - | - |
| Profit / (loss) for the period | (2,098) | 1,76,070 | (5,203) | 1,55,213 |
Quarterly Consolidated Financial Results (Q ended June 30, 2026)
The consolidated results reflect the performance of the Holding Company and its subsidiaries, including SPARCLIFE, Inc. and Genokine Biotech Limited. The unaudited consolidated figures for Q ended June 30, 2026, are as follows:| Particulars | Q ended 30.06.2026 (Unaudited) | Q ended 31.03.2026 (Audited) | Q ended 30.06.2025 (Unaudited) | Year ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from contracts with customers | 3,992 | 1,320 | 964 | 3,915 |
| Other operating revenue | - | 1,84,002 | - | 1,84.002 |
| Total revenue from operations | 3,992 | 1,85,322 | 964 | 1,87,917 |
| Other income | 2,366 | 180 | 914 | 1,095 |
| Total income | 6,358 | 1,85,502 | 1,878 | 1,89,012 |
| Cost of materials consumed | 766 | 516 | 513 | 2,360 |
| Employee benefits expense | 2,961 | 2,602 | 3,132 | 11,803 |
| Clinical trial expenses / products development expense | 1,326 | 284 | 554 | 2,266 |
| Professional charges | 1,519 | 2,930 | 1,007 | 6,948 |
| Finance costs | 813 | 1,164 | 619 | 3,413 |
| Depreciation and amortisation expense | 220 | 240 | 268 | 1,021 |
| Other expenses | 820 | 1,670 | 966 | 4,664 |
| Total expenses | 8,425 | 9,406 | 7,059 | 32,475 |
| Profit / (loss) before exceptional item and tax | (2,067) | 1,76,096 | (5,181) | 1,56,537 |
| Exceptional item | - | - | - | 1,236 |
| Profit / (loss) before tax | (2,067) | 1,76,096 | (5,181) | 1,55,301 |
| Tax expense | 11 | (38) | 6 | (19) |
| Profit / (loss) for the period | (2,078) | 1,76,134 | (5,187) | 1,55,320 |
The company recorded a total comprehensive profit / (loss) for the period of (2,076) lakh in the standalone segment and 1,55,577 lakh on a consolidated basis. Paid-up equity share capital stood at 3,245 lakh across both segments.
SPARC Stock Price Movement
As of 2:13 PM, shares of Sun Pharma Advanced Research Company Limited are slipping by 0.53% in live trading, currently registering at ₹212.07. The stock has seen 657,896 shares traded today, navigating between the daily low of ₹206.7 and a high of ₹216.8.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: